RxDoctor Payments Data

Joan Lee Seltenright

Family · Canton, GANPI 1518058429

Payments from drug & device makers

$1,821in general payments, 2019–2025

Across 91 payments — averaging $20.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$397
  • Takeda Pharmaceuticals U.S.A., Inc.$149
  • Sanofi-aventis U.S. LLC$129
  • Inspire Medical Systems, Inc.$121
  • Boehringer Ingelheim$107
  • Pfizer$99
  • plus $819 from 22 others

What the payments were for

  • Food & beverage$1,821100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,821 in reported general payments places this provider in the 75th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$20,266
Medicare patients
141
Services billed
245

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban22$22,451
JanuviaSitagliptin Phosphate14$12,932
LinzessLinaclotide14$10,459
Advair HfaFluticasone Propion/Salmeterol11$4,640
Incruse ElliptaUmeclidinium Bromide12$3,983
Levothyroxine Sodium159$1,886
Atorvastatin Calcium206$1,483
Losartan Potassium123$935
Albuterol Sulfate HfaAlbuterol Sulfate32$880
Fluticasone Propionate75$787
Buspirone Hcl19$682
Gabapentin41$652
Escitalopram Oxalate47$606
Nifedipine ErNifedipine15$574
Lisinopril88$539

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$99$22,45122 claims
MerckJanuvia$61$12,93214 claims
AbbVieLinzess$22$10,45914 claims
GSKIncruse Ellipta$53$3,98312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,258 family providers in Georgia.

Other family in Canton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →